GSK

News

Relief for GSK as RSV vaccine clears phase 3 test in adults

GSK will start preparations for regulatory filings of its respiratory syncytial virus (RSV) vaccine straight away, after the shot hit the mark in the much-anticipated AReSVi 006 trial in ad

Patients

Conducting successful commercial research in a primary care ...

The primary care setting has garnered significant attention from industry stakeholders due to its promise in commercial research.

News

GSK’s ZEJULA gets green light for NHS use

The UK’s National Institute for Health and Care Excellence (NICE) has recommended GlaxoSmithKline’s (GSK) ZEJULA (niraparib) for some forms of ovarian, fallopian tube, and peritoneal cancer

R&D

US vs EU: How can Europe translate home-grown innovation int...

We have seen a boom in biotech initial public offerings over the last two years, but many of Europe’s offerings have migrated to the United States.

Views & Analysis

Pharma’s pipeline continues to provide drama as investors lo...

While the pandemic has been the focus of R&D attention for much of 2020, that is slowly beginning to shift towards other projects in the big pharma pipeline.

Views & Analysis

Health literacy needs support, now more than ever

The COVID-19 pandemic has brought healthcare guidelines and scientific advances front-of-mind on a global scale, in the process highlighting long-standing gaps in health literacy as well as

Relief for GSK as RSV vaccine clears phase 3 test in adults

Conducting successful commercial research in a primary care ...

GSK’s ZEJULA gets green light for NHS use

US vs EU: How can Europe translate home-grown innovation int...

Pharma’s pipeline continues to provide drama as investors lo...

Health literacy needs support, now more than ever

Roche, Viking, and Syntis showcase obesity drug candidates

Discover a new era of healthcare panel engagement: Grounded ...

GSK

Editor's Picks